Author: OurCrowd

[Alloy Therapeutics in Business Wire] Alloy Therapeutics enters into multi-target collaboration and license agreement with Biogen for use of Alloy’s AntiClastic™ ASO Platform

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform.  Read more...

Read More